{"disease":{"id":"her2-expressing-solid-tumors","name":"her2 expressing solid tumors"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04482309","title":"A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":477,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06154343","title":"A Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"GeneQuantum Healthcare (Suzhou) Co., Ltd.","has_results":false},{"nct_id":"NCT07334119","title":"Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Myeloid Therapeutics","has_results":false},{"nct_id":"NCT06560138","title":"A Trial of SHR-4602 Infusion in Patients With SHR-4602 in Subjects With HER2-expressing or HER2-mutated Locally Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Atridia Pty Ltd.","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}